Blood Test Based on DNA Changes to Help Diagnose Pancreatic Cancer
Tests a blood test for pancreatic cancer using DNA changes in adults.
Plain-language title generated from the registry record
Registry title: Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Key facts
- Where
- Glen Burnie, United StatesSee the site
Where in United States
- University of Maryland Baltimore Washington Medical CenterGlen Burnie, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Maryland, Baltimore
- Trial code
- NCT07528430
- Record updated
- 6 November 2026
- Original description
The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.Read full original descriptionShow less
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.
Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Inclusion: 18 years old or older; Patient of UMMS; Willing and able to consent to study procedures listed in the protocol; Ability to speak and understand English; Has a history of pancreatic cancer of is at high risk for pancreatic cancer.
Exclusion: Does not have a history of pancreatic cancer or is not at high risk for pancreatic cancer; Younger than 18 years old; Patient not cared for at UMMS; Unable to consent to study procedures listed in the protocol; Unable to speak or understand English.